FDA approves pancreatic cancer pill as Tyler patient sees results in similar clinical trial

The FDA has approved daraxonrasib, a pancreatic cancer pill targeting the RAS mutation, which nearly doubles survival for metastatic pancreatic adenocarcinoma patients. A local clinical trial in Tyler, Texas, has shown promising results with minimal side effects, enabling patients significant symptom relief and tumour reduction.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.